Table 4.
Different characteristics according plasma EGFR mutational status
| |
Patients with plasma EGFR mutation |
Patients without plasma EGFR mutation |
P value |
|---|---|---|---|
| (n = 10) | (n = 50) | ||
| Age |
|
|
|
| Median, years |
60.5 |
63.0 |
0.76 |
| Range |
51-76 |
38-84 |
|
| Gender |
|
|
|
| Female |
7 (70.0%) |
32 (64.0%) |
1.00 |
| Male |
3 (30.0%) |
18 (36.0%) |
|
| Smoking history |
|
|
|
| Nonsmoker |
8 (80.0%) |
35 (70.0%) |
0.67 |
| Ex-smoker |
1 (10.0%) |
10 (20.0%) |
|
| Current smoker |
1 (10.0%) |
5 (10.0%) |
|
| WHO Performance status |
|
|
|
| Normal activity |
4 (40.0%) |
19 (38.0%) |
0.94 |
| Restricted activity |
4 (40.0%) |
23 (46.0%) |
|
| In bed < 50% of the time |
2 (20.0%) |
7 (14.0%) |
|
| In bed > 50% of the time |
- |
1 (2.0%) |
|
| Tumor histology |
|
|
|
| ADC |
9 (90.0%) |
44 (88.0%) |
0.83 |
| SQC |
- |
3 (6.0%) |
|
| LCC |
- |
1 (2.0%) |
|
| NSCLC NOS |
1 (10.0%) |
1 (2.0%) |
|
| Others |
- |
1 (2.0%) |
|
| Stage |
|
|
|
| IIIA |
- |
3 (6.0%) |
0.64 |
| IIIB |
1 (10.0%) |
3 (6.0%) |
|
| IV |
9 (90.0%) |
44 (88.0%) |
|
| Central labotory |
|
|
|
| on-site |
5 (50.0%) |
16 (32.0%) |
0.30 |
| off-site | 5 (50.0%) | 34 (68.0%) |
Abbreviations: ADC adenocarcinoma, SQC squamous cell carcinoma LCC large cell carcinoma, NSCLC NOS non-small cell lung cancer not otherwise specified.